GSK-7975A

1253186-56-9

C18H12F5N3O2

DMSO : >= 90 mg/mL (226.53 mM)

Membrane Transporter/Ion Channel; Neuronal Signaling

GSK-7975A is a potent and orally available CRAC channel inhibitor. In Vitro: GSK-7975A reduces FcepsilonRI-dependent Ca²⁺ influx and 3 uM GSK-7975A reduces the release of histamine, leukotriene C4, and cytokines (IL-5/-8/-13 and TNFalpha) by up to 50%^[1]. GSK-7975A inhibits mediator release from mast cells, and pro-inflammatory cytokine release from T-cells in a variety species. GSK-7975A completely inhibits calcium influx through CRAC channels. This leads to inhibition of the release of mast cell mediators and T-cell cytokines from multiple human and rat preparations. Mast cells from guinea-pig and mouse preparations are not inhibited by GSK-7975A; however cytokine release is fully blocked from T-cells in a mouse preparation^[2]. GSK-7975A inhibits toxin-induced activation of ORAI1 and/or activation of Ca²⁺ currents after Ca²⁺ release, in a concentration-dependent manner, in mouse and human pancreatic acinar cells (inhibition >90% of the levels observed in control cells). GSK-7975A also prevents activation of the necrotic cell death pathway in mouse and human pancreatic acinar cells^[3]. In Vivo: GSK-7975A inhibits local and systemic features of acute pancreatitis in TLCS-AP, CER-AP, FAEE-AP, in dose- and time-dependent manners. GSK-7975A significantly reduces increases in serum amylase, IL6, and pancreatic MPO levels; lung MPO is reduced significantly by low dose only. GSK-7975A markedly reduces pancreatic histopathology in TLCS-AP, CER-AP, and FAEE-AP^[3].